Biogen Ma Inc.

Millennium Pharmaceuticals Limited

Sunesis Pharmaceuticals, Inc.

Biogen Idec Ma Inc.

Jeffrey Vessels

Zhili Xin

Gnanasambandam Kumaravel

Kevin Guckian

Nathan Genung

Lei Zhang

Hairuo Peng

Edward Yin Shiang Lin

Ryan Gianatassio

Alexey Alexandrovich Lugovskoy

Hiroko Tanaka

John Howard Jones

Bing Guan

Noel Aaron Powell

Brian Raimundo

Jennifer Cossrow

Thomas Wynn

Weirong Chen

Benjamin Lane

Adam Littke

Lloyd Franklin

Joseph P Lyssikatos

Russell Colyn Petter

Jermaine Thomas

Brian Stuart Lucas

Tracy J Jenkins

Timothy Raymond Chan

Alexey V Ishchenko

James E Dowling

Jeremy Duffield

Gang Yao

Robert Meissner

Irina Leaf

Hexi Chang

Kevin M Guckian

Lioyd Franklin

Described herein are compounds represented by formula (I) (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R, R, R, Y, Y, and Z are as defined herein.

Azetidinyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors

Described herein are compounds represented by formula (I), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R, R, R, Y, Y, m, n, and p are as defined herein.

Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Described herein are compounds represented by formulas (IA) or (IB) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R, R, R, Y, Y, Ar, Z and n are as defined herein.

O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors

O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Described herein are compounds represented by formula (I&#x2033;) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, R, R, m, n, Y, Y, Rand Rare defined herein.

O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors

Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production. Formula (I) The compounds are IRAK-4 inhibitors useful for treating an inflammatory disease, an autoimmune disease, cancer, a cardiovascular disease, a disease of the central nervous system, a disease of the skin, an ophthalmic disease and condition, and a bone disease. 

IRAK4 inhibiting agents

The present invention provides methods of inhibiting Raf kinase activity in a patient, the method comprising administering to the patient a compound having formula I: or a pharmaceutically acceptable salt thereof, wherein R, R, R, L, L, Cy, and Cyare as defined as set forth in the specification.

Substituted pyrimidines for inhibiting Raf kinase activity

The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.

Compounds useful as Raf kinase inhibitors

The present invention provides compounds useful as inhibitors of protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.

Heterocyclic compounds useful as RAF kinase inhibitors

The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula I (See formula on paper copy) 

Triazolopyrazines and methods of making and using the same

Growing community of inventors

Marlborough, MA, United States of America

Jeffrey Vessels